progression or unacceptable toxicity or for up to 35 cycles. The primary endpoint will be PFS. An exploratory analysis on tumor biopsies before and after NAD will be performed, to identify immunogenic and genetic markers of responsiveness or resistance to NAD treatment.

**Results** Trial in progress: there are no available results at the time of submission.

**Conclusions** Trial in progress: there are no available conclusions at the time of submission.

**TP004/#1457**

TRIAL IN PROGRESS OF ENGOT-CX8/GOG-3024/ INNOVATV 205: ADDITION OF A NEW COHORT USING FIRST-LINE TISOTUMAB VEDOTIN + PEMBROLIZUMAB + CARBOPLATIN ± BEVACIZUMAB IN RECURRENT/METASTATIC CERVICAL CANCER

Ignaque Vorgoe, 2Mansoor Mirza, 3Jaidel Sebouli, 4Donorina Lorussa, 5Fatih Köse, 6David Cubila, 7Anneeke Westermann, 8Dharshilla Collins, 9Susana Banerjee, 10Anna Oakes, 11Ibrahima Soumaoro, 12Shweta Jain, 13Bradley Monk.

1Leuven Cancer Institute and BGOG (Belgium and Luxembourg Gynaecological Oncology Group), University Hospitals Leuven, Leuven, Belgium; 2Rigshospitalet, Copenhagen University Hospital, Department of Cancer Treatment, Copenhagen, Denmark; 3Charité University Hospital Campus Virchow Klinikum, Gynecology and Gynecological Oncology, Berlin, Germany; 4Fondazione Policlinico Universitario A.Gemelli IRCCS, Gynecologic Oncology, Rome, Italy; 5Baskent University, Department of Medical Oncology, Yâneşî Adana, Turkey; 6First Faculty of Medicine, Charles University and General University Hospital, Department of Obstetrics and Gynecology, Prague, Czech Republic; 7Dutch Gynaecological Oncology Group (DGOG) and Amsterdam University Medical Centers, Department of Medical Oncology, Amsterdam, Netherlands; 8Cork University Hospital, Department of Medical Oncology, Cork, Ireland; 9The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Gynaecology Unit, London, UK; 10Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, and GEICO, Gynecologic Cancer Programme, Barcelona, Spain; 11Genmab US, Inc., Oncology, Plainsboro, USA; 12Seagen Inc., Late Stage Development, Bothell, USA; 13Director, Principal Investigator, Community Research Development, HonorHealth Research Institute, Division of Gynecologic Oncology, Phoenix, USA

10.1136/ijgc-2022-igcs.513

**Objectives** A 2-part, multicohort, phase 1b/2 trial, ENGOT-cx8/GOG-3024/innovaTV 205 (NCT03786081), established the recommended phase 2 dose (RP2D) and feasibility of tisotumab vedotin (TV) in combination with bevacizumab, pembrolizumab, or carboplatin (Monk et al, IGCS 2021). The current report details a new, ongoing, innovaTV 205 dose-expansion cohort evaluating combinations of TV, pembrolizumab, and carboplatin ± bevacizumab.

**Methods** The new cohort will include adult patients with recurrent or stage IVB squamous, adenosquamous, or adenosquamous of the cervix who received no prior systemic therapy and had an ECOG PS of 0 or 1. Patients will be treated with the RP2D of TV (2.0 mg/kg) + carboplatin (AUC 5 mg/mL), pembrolizumab (200 mg), and bevacizumab (15 mg/kg), or with TV + carboplatin (AUC 5 mg/mL) and pembrolizumab (200 mg), every 3 weeks. To assess the regimen’s initial tolerability, a dose-limiting toxicity evaluation period will consist of completion of 1 treatment cycle of 21 days for 6 patients to receive the quadruplet combination. The primary end point is confirmed objective response per RECIST v1.1; secondary end points are duration of response, time to response, progression-free survival, overall survival, and safety. Enrollment is ongoing in the US and Europe, with additional sites planned globally.

**Results** Trial in progress: there are no available results at the time of submission.

**Conclusions** Trial in progress: there are no available conclusions at the time of submission. ©2022 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2022 ASCO Annual Meeting. All rights reserved.

**TP005/#272**

CONTESSA/NEOCON-F TRIAL: NEOADJUVANT CHEMOTHERAPY FOLLOWED BY FERTILITY-SPARING SURGERY IN FIGO 2018 STAGE IB2 CERVICAL CANCER

1Marie Plante, 2,3Nienke Van Trommel, 4Mrite Schaufsfina, 5Amit Oza, 6Angela Rodriguez, 7Lisa Wang, 8Karolina Sikorska, 9Sarah Ferguson, 10Kathy Han, 11Stephanie Uhereux, 12Frederic Amant. Centre Hospitalier Universitaire de Quebec, Laval University, Division of Gynecologic Oncology, Quebec City, Canada; 13Antoni van Leeuwenhoek – Netherlands Cancer Institute, Gynecologic Oncology, Amsterdam, Netherlands; 14Center for Gynecologic Oncology Amsterdam, Gynecologic Oncology, Amsterdam, Netherlands; 15Amsterdam UMC location Vrije Universiteit, Pathology, Amsterdam, Netherlands; 16Princess Margaret Cancer Centre, University Health Network, Division of Medical Oncology and Hematology, Toronto, Canada; 17Princess Margaret Cancer Centre, University Health Network, Bras Drug Development Program, Toronto, Canada; 18Princess Margaret Centre, University Health Network, Department of Biostatistics, Toronto, Canada; 19Antoni van Leeuwenhoek – Netherlands Cancer Institute, Department of Biostatistics, Amsterdam, Netherlands; 20Princess Margaret Cancer Centre/University Health Network, Gynecology Oncology, Toronto, Canada; 21Princess Margaret Cancer Centre, University Health Network, Department of Radiation Oncology, Toronto, Canada

10.1136/ijgc-2022-igcs.514

**Objectives** The primary objective of the CONTESSA/NEOCON-F trial (NCT04016389) is to assess the feasibility of preserving fertility in women with FIGO 2018 stage IB2 cervical cancer by administering neo-adjuvant chemotherapy (NACT) followed by fertility sparing surgery (FSS).

**Methods** This ongoing multi-center, phase II clinical trial will accrue 90 premenopausal women, aged between 18 and 40 years, who are diagnosed with lymph-node negative, FIGO 2018 stage IB2 cervical cancer and who have a desire to preserve fertility. Patients will receive three cycles paclitaxel and platinum-based chemotherapy. Following NACT the response will be evaluated by clinical examination and MRI. Patients with complete or partial response (residual lesion <2 cm) will be eligible for FSS: a conization or simple trachelectomy. Patients with suboptimal response (residual lesion ≥2 cm) will go off-study and receive definitive treatment as per local protocol. The follow-up is three years. The primary outcome is the rate of functional uterus sparing at the time of submission. Secondary outcomes include the safety of NACT and FSS, the response rate to NACT, and the recurrence-free and overall survival.